Showing results (441-450 of 505) with videos related to
Sort By:
Pageof 51
Alimentary Pharmacology & Therapeutics|December 22, 2017
Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitisF Bär, T Kühbacher, N A Dietrich, et al.Endoscopy|May 31, 2011
Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitisL Favre, F Borle, D Velin, et al.Gut|November 16, 2001
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapsesW Kruis, S Schreiber, D Theuer, et al.Oncogenesis|November 22, 2016
Classic IL-6R signalling is dispensable for intestinal epithelial proliferation and repairK Aden, A Breuer, A Rehman, et al.Journal of Dental Research|February 24, 2010
COX-2 is associated with periodontitis in EuropeansA S Schaefer, G M Richter, M Nothnagel, et al.Gut|January 13, 2006
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitisT Kühbacher, S J Ott, U Helwig, et al.Lancet (London, England)|June 6, 2002
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialStephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, et al.The European Respiratory Journal|May 5, 2011
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1S Hofmann, A Fischer, A Till, et al.Blood|March 9, 2000
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridizationN Zojer, R Königsberg, J Ackermann, et al.Gut|January 13, 2001
Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel diseaseJ Hampe, N J Lynch, S Daniels, et al.Pageof 51